1
Henrik Egesborg Hansen, Henrik Ege, Thomas Munk Plum: Method and apparatus for in vivo determination of the concentration in a body fluid of metabolically significant substances. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, October 28, 1997: US05680858 (401 worldwide citation)

A method for in vivo determination of the concentration in a body fluid of metabolically significant substance comprises storing of a needle with a sensor in a liquid-filled ampoule, brief insertion of the needle into a patient, recording of the output signal from the sensor, withdrawal of the needl ...


2
Jan Wojcicki, Boguslaw Lilpop, Marek Ziembicki, Stanislaw Bielawski: Device for monitoring the operation of a delivery system and the method of use thereof. Institute of Biocybernetics and Biomedical Engineering P, Novo Nordisk, Steve T Zelson, Elias J Lambiris, March 2, 1993: US05190522 (255 worldwide citation)

A device for monitoring a delivery system comprising a volumetric micropump, a measuring element or sensor located in the infusion line, a matching system and an analyzing system. The devices are preferably for use in insulin administration when treating type-I diabetes and in analytical laboratorie ...


3
Steffen Hansen, Peter Christian Klitgaard: Dose display for an injection syringe. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, September 7, 1999: US05947934 (152 worldwide citation)

The present invention relates to injection syringes comprising a housing accommodating an ampoule containing medicine sufficient for a number of dosed injections. The syringe has a dose setting mechanism by which doses may be set by rotating a dose setting element relative to the housing and the dos ...


4
Martin Schulein, Kirsten B o slashed egh Levring: Methods for reducing the harshness of a cotton-containing fabric. Novo Nordisk, Steve T Zelzon Esq, Elias J Lambiris Esq, July 15, 1997: US05648263 (142 worldwide citation)

The present invention relates to methods of reducing the rate at which a cotton-containing fabric becomes harsh or of reducing the harshness of a cotton-containing fabric, comprising treating the cotton-containing fabric with a cellulase preparation obtained from a fungus, wherein the cellulase prep ...


5
Martin Schulein, Kirsten B o slashed egh Levring: Fungal cellulase composition containing alkaline CMC-endoglucanase and essentially no cellobiohydrolase and method of making thereof. Novo Nordisk, Steve T Zelson, Elias J Lambiris, July 7, 1998: US05776757 (136 worldwide citation)

A cellulase preparation useful for reducing the harshness of cotton-containing fabrics and for reducing the rate at which such fabrics become harsh comprises about 40% or more (based on the total protein content) of an endoglucanase component with a pH optimum of about 7.5-10.0 with a high CMC-endoa ...


6
Martin Schulein, Kirsten B o slashed egh Levring: Fungal cellulase composition containing alkaline CMC-endoglucanase and essentially no cellobiohydrolase. Novo Nordisk, Steve T Zelson, Elias J Lambiris, November 25, 1997: US05691178 (135 worldwide citation)

A cellulase preparation useful for reducing the harshness of cotton-containing fabrics and for reducing the rate at which such fabrics become harsh comprises about 40% or more (based on the total protein content) of an endoglucanase component with a pH optimum of about 7.5-10.0 with a high CMC-endoa ...


7
Liselotte Bjerre Knudsen, Per Olaf Huusfeldt, Per Franklin Nielsen, Niels C Kaarsholm, Helle Birk Olsen, Søren Erik Bjørn, Freddy Zimmerdahl Pedersen, Kjeld Madsen: Derivatives of GLP-1 analogs. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, July 31, 2001: US06268343 (103 worldwide citation)

The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.


8
Ulla K E Hedner: Method for the treatment of bleeding disorders. Steve T Zelson, Elias J Lambiris, January 19, 1993: US05180583 (89 worldwide citation)

A method for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, as well as a novel composition for use in treating bleeding disorders as disclosed. The method includes administering to a patient a composition comprising an effecti ...


9
Allan Svendsen, Shamkant Anant Patkar, Erik Gormsen, Jens Sigurd Okkels, Marianne Thellersen: Lipase variants. Novo Nordisk, Steve T Belson, Elias J Lambiris, February 9, 1999: US05869438 (89 worldwide citation)

The present invention relates to lipase variants which exhibit improved properties, detergent compositions comprising said lipase variants, DNA constructs coding for said lipase variants, and methods of making said lipase variants.


10
Helle F Woldike, Fred Hagen, Carsten Hjort, Sven Hastrup: Enzyme capable of degrading cellullose or hemicellulose. Novo Nordisk, Steve T Zelson, Elias J Lambiris, October 10, 1995: US05457046 (70 worldwide citation)

A cellulose- or hemicellulose-degrading enzyme which is derivable from a fungus other than Trichoderma or Phanerochaete, and which comprises a carbohydrate binding domain homologous to a terminal A region of Trichoderma reesei cellulases, which carbohydrate binding domain amino acid sequence (.alpha ...